Skip to main content
. 2020 Mar;61(3):327–336. doi: 10.2967/jnumed.119.230037

TABLE 1.

Demographic and Clinical Characteristics of Study Cohort

Total (n = 162) Training (n = 81) Validation (n = 81) P
Median age (y) 62.4 (SD, 9.8) 64.3 (SD, 11.2) 62.0 (SD, 8.2) 0.138
Sex (n) 1.0
 Male 149 (92.0%) 74 (91.4%) 75 (92.6%)
 Female 13 (8.0%) 7 (8.6%) 6 (7.4%)
T category (AJCC 7th ed.) (n) 0.987
 T1 20 (12.3%) 10 (12.3%) 10 (12.3%)
 T2 58 (35.8%) 30 (37.0%) 28 (34.6%)
 T3 46 (28.4%) 23 (28.4%) 23 (28.4%)
 T4 38 (23.5%) 18 (22.2%) 20 (24.7%)
N category (AJCC 7th ed.) (n) 0.483
 N0 8 (4.9%) 6 (7.4%) 2 (2.5%)
 N1 15 (9.3%) 7 (8.6%) 8 (9.9%)
 N2 125 (77.2%) 60 (74.1%) 65 (80.2%)
 N3 14 (8.6%) 8 (9.9%) 6 (7.4%)
Stage (AJCC 7th ed.) (n) 1.0
 I 1 (0.6%) 1 (1.2%) 0 (0%)
 II 1 (0.6%) 0 (0%) 1 (1.2%)
 III 13 (8.0%) 7 (8.6%) 6 (7.4%)
 IV 147 (90.7%) 73 (90.1%) 74 (91.4%)
p16 status (HPV) (n) 0.812
 + 142 (87.7%) 70 (86.4%) 72 (88.%9)
 − 20 (12.3%) 11 (13.6%) 9 (11.1%)
Smoking history (n) 1.0
 >10 pack-years 60 (37.0%) 30 (37.0%) 30 (37.0%)
 ≤10 pack-years 102 (63.0%) 51 (63.0%) 51 (63.0%)
PFS (n) 1.0
 No 37 (22.8%) 18 (22.2%) 19 (23.5%)
 Yes 125 (77.2%) 63 (77.8%) 62 (76.5%)
Median follow-up (y) 2.1 (SD, 1.3) 2.1 (SD, 1.4) 2.1 (SD, 1.3) 1.0
2-y PFS (n) 1.0
 No 32 (19.8%) 16 (19.8%) 16 (19.8%)
 Yes 130 (80.2%) 65 (80.2%) 65 (80.2%)